Celcuity, Inc. (NASDAQ:CELC) Stock Rated "Moderate Buy" by Wall Street Analysts

Key Points

• Celcuity has a “Moderate Buy” consensus rating from 12 analysts, with 11 buys and one sell; the average 12-month price target is $154.25.
• Institutional investors own 63.33% of the company, with several major funds—including Avoro Capital Advisors, Bank of America, and Wellington Management—recently acquiring or increasing positions.
• Shares opened at $75.13, down 5.5%, and remain well below their 52-week high of $151.02. Celcuity also reported a quarterly EPS loss of $1.44, missing the $1.16 consensus estimate.

Celcuity, Inc. (NASDAQ:CELC - Get Free Report) has received an average rating of "Moderate Buy" from the twelve ratings firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating and eleven have issued a buy rating on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $154.25.

CELC has been the topic of several research analyst reports. Weiss Ratings reissued a "sell (d-)" rating on shares of Celcuity in a report on Tuesday, September 1st. Stifel Nicolaus cut their price objective on Celcuity from $175.00 to $150.00 and set a "buy" rating for the company in a report on Friday, August 14th. Wall Street Zen cut Celcuity from a "sell" rating to a "strong sell" rating in a research report on Saturday, August 15th. JPMorgan Chase & Co. began coverage on Celcuity in a report on Thursday, September 17th. They issued an "overweight" rating and a $157.00 target price on the stock. Finally, Craig Hallum reissued a "buy" rating and issued a $178.00 target price on shares of Celcuity in a research report on Wednesday, July 15th.

Hedge Funds Weigh In On Celcuity

Several institutional investors have recently made changes to their positions in CELC. Avoro Capital Advisors LLC bought a new stake in Celcuity during the fourth quarter valued at approximately $310,302,000. Bank of America Corp DE bought a new position in Celcuity in the second quarter worth approximately $153,928,000. Wellington Management Group LLP raised its position in Celcuity by 111.4% in the second quarter. Wellington Management Group LLP now owns 906,595 shares of the company's stock worth $94,848,000 after acquiring an additional 477,643 shares during the period. Geode Capital Management LLC boosted its stake in shares of Celcuity by 8.4% during the 4th quarter. Geode Capital Management LLC now owns 830,684 shares of the company's stock worth $82,872,000 after acquiring an additional 64,213 shares during the last quarter. Finally, Capitolis Liquid Global Markets LLC purchased a new position in shares of Celcuity during the 4th quarter worth $35,428,000. Institutional investors own 63.33% of the company's stock.

Celcuity Stock Down 5.5%

Shares of Celcuity stock opened at $75.13 on Friday. The company has a market cap of $3.68 billion, a price-to-earnings ratio of -17.47 and a beta of 0.11. The company's 50 day moving average is $87.73 and its 200 day moving average is $103.15. Celcuity has a twelve month low of $44.42 and a twelve month high of $151.02. The company has a quick ratio of 8.93, a current ratio of 8.93 and a debt-to-equity ratio of 6.04.

Celcuity (NASDAQ:CELC - Get Free Report) last issued its earnings results on Thursday, August 13th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.16) by ($0.28). Research analysts anticipate that Celcuity will post -4.82 EPS for the current year.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company that develops functional diagnostic tests designed to help identify patients who may benefit from targeted cancer therapies. The company's technology is intended to measure the activity of cellular signaling networks in living tumor cells, rather than relying solely on the presence or absence of individual biomarkers.

Celcuity's proprietary CELsignia platform analyzes patient tumor samples to identify abnormal signaling activity associated with cancer growth and treatment response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.